Cover Image
市場調查報告書

胰島類澱粉多胜肽:開發中產品分析

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 368713
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
胰島類澱粉多胜肽:開發中產品分析 Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 52 Pages
簡介

本報告提供以胰島類澱粉多胜肽為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胰島類澱粉多胜肽 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adocia
  • AstraZeneca Plc
  • Neurimmune Holding AG
  • Nordic Bioscience A/S
  • reMYND NV
  • Zealand Pharma AS

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0781TDB

Summary

According to the recently published report 'Islet Amyloid Polypeptide - Pipeline Review, H1 2017'; Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.

The report 'Islet Amyloid Polypeptide - Pipeline Review, H1 2017' outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Musculoskeletal Disorders, Gastrointestinal and Central Nervous System which include indications Type 2 Diabetes, Obesity, Osteoarthritis, Type 1 Diabetes (Juvenile Diabetes), Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease and Non Alcoholic Fatty Liver Disease (NAFLD).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)targeted therapeutics and enlists all their major and minor projects
  • The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
    • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
    • Adocia
    • AstraZeneca Plc
    • Neurimmune Holding AG
    • Nordic Bioscience A/S
    • reMYND NV
    • Zealand Pharma AS
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
    • (insulin human + pramlintide acetate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (insulin lispro + pramlintide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AC-253 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KBP-042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KBP-056 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KBP-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReS-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReS-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • salmon calcitonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UGP-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-4982 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-5461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
      • Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
      • Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions
      • Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042
      • May 05, 2014: reMYND's novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models
      • Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
      • Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease
      • Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Adocia, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by Neurimmune Holding AG, H1 2017
  • Pipeline by Nordic Bioscience A/S, H1 2017
  • Pipeline by reMYND NV, H1 2017
  • Pipeline by Zealand Pharma AS, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top